N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine
C22H30F2N6 — CID 167500088
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine
N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine (PubChem CID 167500088) has the molecular formula C22H30F2N6 and a molecular weight of 416.52 g/mol. Its IUPAC name is N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine.
Molecular Properties
| Compound Name | N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine |
|---|---|
| PubChem CID | 167500088 |
| Molecular Formula | C22H30F2N6 |
| Molecular Weight | 416.52 g/mol |
| Exact Mass | 416.25 |
| IUPAC Name | N-[6-(3,3-difluoropyrrolidin-1-yl)-4-(1-propan-2-ylpiperidin-4-yl)-2-pyridinyl]-5-methylpyrazin-2-amine |
| SMILES | Cc1cnc(Nc2cc(C3CCN(C(C)C)CC3)cc(N3CCC(F)(F)C3)n2)cn1 |
| InChI | InChI=1S/C22H30F2N6/c1-15(2)29-7-4-17(5-8-29)18-10-19(27-20-13-25-16(3)12-26-20)28-21(11-18)30-9-6-22(23,24)14-30/h10-13,15,17H,4-9,14H2,1-3H3,(H,26,27,28) |
| InChIKey | UFKLFYGNKYPEHJ-UHFFFAOYSA-N |
| XLogP | 4.36 |
| TPSA | 57.18 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 416.52 |
| LogP ≤ 5 | 4.36 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 167500088 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.